Osteopontin in Vascular Disease
- PMID: 30727754
- PMCID: PMC6436981
- DOI: 10.1161/ATVBAHA.118.311577
Osteopontin in Vascular Disease
Abstract
Inflammatory cytokines are necessary for an acute response to injury and the progressive healing process. However, when this acute response does not resolve and becomes chronic, the same proteins that once promoted healing then contribute to chronic inflammatory pathologies, such as atherosclerosis. OPN (Osteopontin) is a secreted matricellular cytokine that signals through integrin and CD44 receptors, is highly upregulated in acute and chronic inflammatory settings, and has been implicated in physiological and pathophysiologic processes. Evidence from the literature suggests that OPN may fit within the Goldilocks paradigm with respect to cardiovascular disease, where acute increases are protective, attenuate vascular calcification, and promote postischemic neovascularization. In contrast, chronic increases in OPN are clinically associated with an increased risk for a major adverse cardiovascular event, and OPN expression is a strong predictor of cardiovascular disease independent of traditional risk factors. With the recent finding that humans express multiple OPN isoforms as the result of alternative splicing and that these isoforms have distinct biologic functions, future studies are required to determine what OPN isoform(s) are expressed in the setting of vascular disease and what role each of these isoforms plays in vascular disease progression. This review aims to discuss our current understanding of the role(s) of OPN in vascular disease pathologies using evidence from in vitro, animal, and clinical studies. Where possible, we discuss what is known about OPN isoform expression and our understanding of OPN isoform contributions to cardiovascular disease pathologies.
Keywords: atherosclerosis; cytokines; inflammation; osteopontin; risk factors; vascular diseases.
Figures
References
-
- Scatena M, Liaw L and Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arteriosclerosis, thrombosis, and vascular biology 2007;27:2302–9. - PubMed
-
- Myers DL, Harmon KJ, Lindner V and Liaw L. Alterations of arterial physiology in osteopontin-null mice. Arterioscler Thromb Vasc Biol 2003;23:1021–8. - PubMed
-
- O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM and Giachelli CM. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994;14:1648–56. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
